Indo National Board Recommends ₹3.75 Dividend; Approves Q4 FY26 Results
Indo National Limited approved Q4 FY26 results with a recommended dividend of ₹3.75 per share. Standalone loss after tax was ₹808.03 Lakhs for the quarter and ₹1,039.71 Lakhs for the year. Consolidated loss after tax was ₹2,099.91 Lakhs for the quarter and ₹2,669.20 Lakhs for the year.
The recommendation of a dividend and the approval of financial results are material events for shareholders. However, the reported losses temper the immediate positive impact.
While the company is recommending a dividend, the financial results show a loss for both the quarter and the full year, leading to a neutral sentiment.
Indo National Limited announced that its Board of Directors, in a meeting held on May 15, 2026, has approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board has recommended a final dividend of ₹3.75 per share (75%) for the financial year ended March 31, 2026, subject to shareholder approval.
The company also reported re-appointment of the Cost Auditor and Internal Auditor. The financial results will be published in newspapers as per SEBI regulations. The meeting commenced at 3:30 PM IST and concluded at 5:00 PM IST.
The audited standalone financial results for the quarter ended March 31, 2026, show a total income of ₹10,790.30 Lakhs and a loss after tax of ₹808.03 Lakhs. For the full year ended March 31, 2026, the total income was ₹45,820.77 Lakhs, with a loss after tax of ₹1,039.71 Lakhs. The earnings per share (EPS) for the year was ₹(13.86).
Consolidated results for the quarter ended March 31, 2026, indicate a total income of ₹10,867.49 Lakhs and a loss after tax of ₹2,099.91 Lakhs. For the full year ended March 31, 2026, consolidated total income stood at ₹46,010.46 Lakhs, with a consolidated loss after tax of ₹2,669.20 Lakhs. The consolidated EPS for the year was ₹(35.12).
Key notes from the financial statements include the amalgamation of Helios Strategic Systems Limited with Indo-National Limited, effective from April 2, 2026. The company also made investments in MEDCUORE MEDICAL SOLUTIONS PRIVATE LIMITED and AXIAL AERO PRIVATE LIMITED during the year. A provision of ₹422 Lakhs has been made in relation to a CCI penalty case, with an appeal filed.
What to do with a filing like this
Indo-National Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indo-National Limited. Read the original for the full detail.